Literature DB >> 13680328

Early treatment with oral immunosuppressants in severe proteinuric purpura nephritis.

Salvatore Li Volti, Giovanni Li Volti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 13680328     DOI： 10.1007/s00467-003-1272-4

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


× No keyword cloud information.
  13 in total

1.  Treatment of Henoch-Schönlein Purpura glomerulonephritis in children with high-dose corticosteroids plus oral cyclophosphamide.

Authors:  J T Flynn; W E Smoyer; T E Bunchman; D B Kershaw; A B Sedman
Journal:  Am J Nephrol       Date:  2001 Mar-Apr       Impact factor: 3.754

2.  Effective therapy for severe Henoch-Schonlein purpura nephritis with prednisone and azathioprine: a clinical and histopathologic study.

Authors:  B J Foster; C Bernard; K N Drummond; A K Sharma
Journal:  J Pediatr       Date:  2000-03       Impact factor: 4.406

3.  Corticosteroid therapy in Henoch-Schönlein purpura.

Authors:  W Lane; M Robson; A K Leung
Journal:  Pediatr Nephrol       Date:  1993-08       Impact factor: 3.714

4.  Early treatment with oral immunosuppressants in severe proteinuric purpura nephritis.

Authors:  Hiroshi Tanaka; Koichi Suzuki; Tohru Nakahata; Etsuro Ito; Shinobu Waga
Journal:  Pediatr Nephrol       Date:  2003-03-28       Impact factor: 3.714

5.  Mechanism of action of glucocorticosteroids. Inhibition of T cell proliferation and interleukin 2 production by hydrocortisone is reversed by leukotriene B4.

Authors:  J S Goodwin; D Atluru; S Sierakowski; E A Lianos
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

6.  Severe Henoch-Schönlein nephritis: resolution with azathioprine and steroids.

Authors:  Surjit Singh; Lata Kumar; Kusum Joshi; Ranjana W Minz; Usha Datta
Journal:  Rheumatol Int       Date:  2002-07-05       Impact factor: 2.631

7.  Incidence of renal complications in Schönlein-Henoch purpura syndrome in dependence of an early administration of steroids.

Authors:  J Buchanec; V Galanda; S Beláková; M Minárik; M Zibolen
Journal:  Int Urol Nephrol       Date:  1988       Impact factor: 2.370

8.  Henoch-Schönlein nephritis: long-term prognosis of unselected patients.

Authors:  O Koskimies; S Mir; J Rapola; J Vilska
Journal:  Arch Dis Child       Date:  1981-06       Impact factor: 3.791

9.  Circulating immune complexes containing IgA, IgG and IgM in patients with primary IgA nephropathy and with Henoch-Schoenlein nephritis. Correlation with clinical and histologic signs of activity.

Authors:  R Coppo; B Basolo; G Martina; C Rollino; M De Marchi; F Giacchino; G Mazzucco; M Messina; G Piccoli
Journal:  Clin Nephrol       Date:  1982-11       Impact factor: 0.975

10.  Multiple combined therapy for severe Henoch-Schönlein nephritis in children.

Authors:  K Iijima; S Ito-Kariya; H Nakamura; N Yoshikawa
Journal:  Pediatr Nephrol       Date:  1998-04       Impact factor: 3.714
View more
  1 in total

1.  Mycophenolate mofetil following glucocorticoid treatment in Henoch-Schönlein purpura nephritis: the role of early initiation and therapeutic drug monitoring.

Authors:  Agnes Hackl; Jan U Becker; Lisa M Körner; Rasmus Ehren; Sandra Habbig; Eva Nüsken; Kai-Dietrich Nüsken; Kathrin Ebner; Max C Liebau; Carsten Müller; Martin Pohl; Lutz T Weber
Journal:  Pediatr Nephrol       Date:  2017-11-25       Impact factor: 3.714
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.